Variable
Mean ± SD
Older recipients (n=33) Younger recipients (n=33) P-value
Age (years) 73.6 ± 2.7 55.3 ±11.4 <0.001
Males 16 (48%) 11 (33%) NS
African American 8 (24%) 13 (39%) NS
Recipient BMI (kg/m2) 26.5 ± 4.7 26.6 ± 5.3 NS
Duration of dialysis (months) 29.2 ± 22.5 29.0 ± 26.6 NS
Time on waiting list (months) 15 ± 11 16 ± 16.5 NS
Renal replacement therapy pretransplant
-Hemodialysis
-Peritoneal dialysis
  24 (73%)
4 (12%)
  24 (73%)
6 (18%)
  NS
NS  
Preemptive transplant 5 (15%) 3 (9%) NS
Retransplant 1 (3%) 1 (3%) NS
Number of HLA mismatches
- 0
- 1-3
- 4-6
  0
9
24
  0
2
31
    0.04
Cause of end stage renal disease
Diabetes
Hypertension
Other
  14 (42%)
9 (27%)
10 (30%)
  10 (30%)
3 (9%)
20 (61%)
    NS
Panel reactive antibody levels
- 0-10%
- 11-49%
- 50-100%
  22
5
6
  31
1
1
  0.01
Cold ischemia (hours) 24.6 ± 8.8 25.1 ± 7.1 NS
Induction immunosuppression
-Alemtuzumab
-Rabbit antithymocyte globulin
-Basiliximab
  25
8
0
  25
7
1
  NS
Maintenance Immunosuppression
- Tacrolimus + MycophenolateMofetil
- Tacrolimus + MycophenolateMofetil + Prednisone
- Cyclosporine + MycophenolateMofetil
- Cyclosporine + MycophenolateMofetil + Prednisone
  12
17 0
4
  12
18 2
1
  NS
Table 1: Demographic and transplant characteristics between older and younger recipient groups.